Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab, Lenvatinib, and XELOX in Advanced Biliary Tract Tumors
NCT05291052Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, lenvatinib in biliary tract cancer (BTC), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
tislelizumablenvatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05291052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291052.